Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (291-300 of 688) with videos related to

Pageof 69
Sort By:
European Journal of Heart Failure|October 2, 2015
Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database InitiativeThomas G von Lueder, Nicolas Girerd, Dan Atar, et al.
Journal of the American Heart Association|June 6, 2024
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney DiseaseIxchel Lima Posada, Matthieu Soulié, Yohan Stephan, et al.
European Heart Journal|December 8, 2022
Prevention of cardiorenal damage: importance of albuminuriaLuis M Ruilope, Alberto Ortiz, Alejandro Lucia, et al.
Journal of the American College of Cardiology|January 18, 2006
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein levelBarry E Bleske, John M Nicklas, Robert L Bard, et al.
Lancet (London, England)|December 11, 2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trialMichael A Weber, Kenneth Jamerson, George L Bakris, et al.
European Journal of Heart Failure|April 7, 2011
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment studyBertram Pitt, Roberto Latini, Aldo P Maggioni, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2021
Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fractionStefano Coiro, Nicolas Girerd, John J V McMurray, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 7, 2019
Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction InitiativeSusan Stienen, João Pedro Ferreira, Nicolas Girerd, et al.
American Journal of Nephrology|October 31, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease TrialLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Journal of Hypertension|September 19, 2014
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart diseaseSusan Cheng, Amil M Shah, Juan Pablo Albisu, et al.
Pageof 69

Showing results (291-300 of 688) with videos related to

Sort By:
Pageof 69
European Journal of Heart Failure|October 2, 2015
Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database InitiativeThomas G von Lueder, Nicolas Girerd, Dan Atar, et al.
Journal of the American Heart Association|June 6, 2024
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney DiseaseIxchel Lima Posada, Matthieu Soulié, Yohan Stephan, et al.
European Heart Journal|December 8, 2022
Prevention of cardiorenal damage: importance of albuminuriaLuis M Ruilope, Alberto Ortiz, Alejandro Lucia, et al.
Journal of the American College of Cardiology|January 18, 2006
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein levelBarry E Bleske, John M Nicklas, Robert L Bard, et al.
Lancet (London, England)|December 11, 2012
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trialMichael A Weber, Kenneth Jamerson, George L Bakris, et al.
European Journal of Heart Failure|April 7, 2011
Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment studyBertram Pitt, Roberto Latini, Aldo P Maggioni, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|May 6, 2021
Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fractionStefano Coiro, Nicolas Girerd, John J V McMurray, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|April 7, 2019
Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction InitiativeSusan Stienen, João Pedro Ferreira, Nicolas Girerd, et al.
American Journal of Nephrology|October 31, 2019
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease TrialLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Journal of Hypertension|September 19, 2014
Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart diseaseSusan Cheng, Amil M Shah, Juan Pablo Albisu, et al.
Pageof 69